Mycamine (micafungin) / Astellas - LARVOL DELTA

Clinical and microbiological insights into invasive fusariosis following allogeneic hematopoietic stem cell transplantation: A 15-year single-center analysis (ASH 2025) - "Baseline characteristics betweenpatients with and without IF were compared using appropriate parametric and non-parametric tests.Overall survival (OS), and day 28, 84, and 1-year mortality were estimated using the Kaplan–Meiermethod, and univariate comparisons of clinical factors—including age, sex, performance status,conditioning intensity, prior HSCT, neutrophil recovery, monotherapy vs combination therapy withliposomal amphotericin B (L-AMB) and voriconazole (VRCZ), and steroid use—were conducted using thelog-rank test. Seventeen patients with proven IF and 2,342 without IF were analyzed...All patients received antifungalprophylaxis: micafungin (n = 10), posaconazole (n = 4), or VRCZ (n = 3)... Seventeen patients with proven IF and 2,342 without IF were analyzed. The incidence of IFamong allogeneic HSCT recipients was 7.2 cases per 1,000 transplants. Most cases occurred in patientstransplanted in non-complete remission (94.1% vs."

Clinical • Bone Marrow Transplantation • Cerebral Hemorrhage • CNS Disorders • Hematological Malignancies • Infectious Disease • Neutropenia • Septic Shock • Transplantation

Fungal infections following chimeric antigen receptor T-cell (CAR-T) cell therapy: A retrospective case-control study in the south-central US (ASH 2025) - "Twopatients had bloodstream infections (BSI) breaking through micafungin, one with Cryptococcusneoformans, and one with Candida krusei. Another three patients broke through fluconazole, one withCandida glabrata BSI, one with Candida krusei BSI and one with Aspergillus pneumonia. The last twopatients broke through posaconazole, one with invasive aspergillosis and one with Trichodermapneumonia... While uncommon, invasive fungal infections tend to occur early after CAR-T therapy and are associatedwith markedly increased mortality despite antifungal prophylaxis. Patients with B-ALL, particularly thosewith a prior allogeneic HCT, patients with prolonged neutropenia or CMV reactivation after CAR T, seemto be at the highest risk. Larger prospective studies are needed to identify the subset of CAR-T recipientsto target for individualized antifungal prophylactic strategies."

CAR T-Cell Therapy • Retrospective data • Hematological Malignancies • Infectious Disease • Lymphoma • Multiple Myeloma • Neutropenia • Pneumonia • Respiratory Diseases

Candida glabrata vertebral osteomyelitis following L3-4 transforaminal lumbar fusion: illustrative case. (PubMed, J Neurosurg Case Lessons) - "This case highlights the diagnostic and therapeutic challenges of postoperative C. glabrata vertebral osteomyelitis. Early suspicion, culture confirmation, and organism-specific antifungal therapy, alongside timely surgical management, are critical to achieving infection control and preserving spinal stability in immunosuppressed patients. https://thejns.org/doi/10.3171/CASE25555."

Journal • Infectious Disease • Inflammation • Orthopedics

Echinocandin tolerance and persistence in vitro are regulated by calcineurin signaling in Candida glabrata. (PubMed, mBio) - "In time-kill assays with micafungin in vitro, the opportunistic pathogen Candida glabrata exhibited biphasic kinetics of cell death...This study utilizes detailed experimental protocols and genome-wide screens to discover how Candida glabrata induces tolerance and persistence to a major class of antifungals. The findings suggest that a clinical immunosuppressant may be repurposed to combat tolerance and persistence in this pathogenic yeast, as well as Candida albicans and perhaps other species."

Journal • Preclinical • Infectious Disease

Identification of Potential Nontoxic Human BTK Inhibitors through an Integrated Deep Learning and Structure-Based Drug Repositioning Strategy. (PubMed, ACS Omega) - "While the BTK inhibitors, including ibrutinib, have shown significant inhibitory potential, their low potency and higher toxicity emphasize the need for safer and more effective alternatives. Finally, the GNN-based toxicity analysis revealed that the suggested compounds did not exhibit any significant toxicity concern, supporting their safety as potential therapeutic agents. These findings contribute to the advancement of safer and more effective treatments for autoimmune diseases and require further clinical trials of gozetotide, micafungin, and candicidin as BTK-targeted therapies."

Journal • Immunology

Species Distribution and Antifungal Susceptibility of Fungal Blood Isolates over a 16-Year Period at a University Hospital. (PubMed, Med Mycol J) - "Antifungal susceptibility to three azoles and micafungin was assessed using the Clinical and Laboratory Standards Institute guidelines, M27-A3 (2008) and M27M44S ED3 (2022)...The findings revealed high susceptibility rates for C. albicans, C. glabrata, and C. parapsilosis to fluconazole, itraconazole, and voriconazole under the 2008 criteria (S + SDD = 89.5%-100%)...These results indicate that antifungal susceptibility among fungal blood isolates has remained stable, except decreasing susceptibility of C. tropicalis to azoles. Continuous surveillance is essential to inform the optimization of treatment strategies for invasive fungal infections."

Journal • Infectious Disease

Use of Aztreonam-Avibactam with Rapid Eravacycline Step-Down Therapy for a Tibial Septic Non-Union by NDM-Producing Enterobacter cloacae. (PubMed, Antibiotics (Basel)) - "Cultures grew Enterobacter cloacae complex resistant to meropenem, ceftazidime-avibactam, meropenem-vaborbactam, and cefiderocol, as well as Candida parapsilosis...The patient was treated with ATM-AVI plus micafungin, achieving clinical stability within three days...At eight-week follow-up, the patient remained clinically improved without relapse or adverse effects. This case highlights ATM-AVI as a critical therapy for NDM-producing orthopedic infections involving hardware and supports eravacycline as a feasible step-down option in outpatient management."

Journal • Infectious Disease • Musculoskeletal Diseases • Orthopedics

Pleurocutaneous fistula in a patient with non-albicans Candida empyema thoracis and spontaneous oesophagopleural fistula. (PubMed, BMJ Case Rep) - "Chest tube thoracostomy was performed, and pleural cultures yielded Candida glabrata, for which micafungin was initiated...Despite these interventions, she developed nosocomial pneumonia with respiratory failure. This case underscores the importance of early fistula closure, adequate pleural drainage and culture-guided antimicrobial therapy for optimal management."

Journal • Infectious Disease • Pneumonia • Respiratory Diseases

Phylogenomic diversity of clinical Saccharomyces cerevisiae and the prevalence of probiotic-derived isolates in a tertiary care center in Hungary. (PubMed, Microbiol Spectr) - "Caspofungin and anidulafungin retained consistent in vitro activity, whereas amphotericin B and micafungin exhibited broader MIC distributions. By integrating genome sequencing, antifungal susceptibility testing, and patient data, we demonstrate that yeasts considered safe in food and probiotic products may nevertheless cause infections in vulnerable individuals. These findings highlight the need for clade-level molecular genetic typing of Saccharomyces samples, cautious probiotic administration, and sustained clinical vigilance."

Journal • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Pediatrics

Community-Onset Fungemias: Epidemiology and Genomic Characterization at a Tertiary-Care Hospital in Barcelona, Spain. (PubMed, J Fungi (Basel)) - "No isolate was resistant to anidulafungin, micafungin, or amphotericin B; one N. glabratus showed reduced susceptibility to caspofungin. Echinocandin resistance was not observed; azole resistance was uncommon. WGS provided precise speciation and actionable insight into resistance mechanisms, including a putatively novel PDR1 G857V in N. glabratus."

Journal • Cardiovascular • Infectious Disease

Phylogenomic analysis and genetic mechanisms of antifungal resistance in clinical isolates of Candida glabrata (Nakaseomyces glabratus) from across Canada, 2013-2020. (PubMed, Microbiol Spectr) - "We also identified specific mutations that may be linked to resistance to commonly used antifungal drugs, such as fluconazole and micafungin. Our research shows how valuable whole-genome sequencing is for understanding the spread and drug resistance of C. glabrata, which can help improve treatment and infection control."

Journal • Infectious Disease

Association between genomic single nucleotide polymorphisms and susceptibility of Talaromyces marneffei. (PubMed, Fungal Genet Biol) - "To reveal the association between genomic single nucleotide polymorphisms (SNPs) and susceptibility to T. marneffei, we sequenced the genomes of 15 clinical isolates of T. marneffei and analyzed the association between their SNPs and susceptibilities to 5-fluorouracil, anidulafungin, posaconazole, voriconazole, fluconazole, caspofungin, amphotericin B, micafungin, and itraconazole. Nine, one, one, and 14 SNP loci were potentially correlated with fluconazole, micafungin, posaconazole, and caspofungin susceptibilities, respectively. These results provide valuable genomic data for further analysis of drug resistance mechanisms and treatment strategies."

Journal • Infectious Disease

Multicentre investigation of Wickerhamomyces anomalus fungemia in India: emerging resistance and mechanistic insights. (PubMed, J Antimicrob Chemother) - "This multicentre study demonstrates the emergence of fluconazole-NWT W. anomalus in Indian hospitals, predominantly affecting neonates, with a high mortality. Resistance was associated with ERG11 mutations, efflux pump overexpression and biofilm formation. These findings highlight that the drug-resistant W. anomalus fungemia is an emerging concern."

Journal • Acute Respiratory Distress Syndrome • Respiratory Diseases • ABCB1

Bad to the bone: Candida (Candidozyma) auris vertebral osteomyelitis treated with combination antifungal therapy followed by a novel long-acting echinocandin. (PubMed, ASM Case Rep) - "Initial treatment included dual antifungal therapy with liposomal amphotericin B and micafungin, selected based on in vitro susceptibility and preclinical synergy data. It also demonstrates the feasibility of using rezafungin as an option for long-term outpatient management. Given the limited clinical experience with combination therapy and rezafungin use, further data are needed to inform standardized treatment approaches."

Journal • CNS Disorders • Infectious Disease • Inflammation • Migraine • Pain

Incidence of Invasive Fungal Infections in CAR T-Cell Therapy Recipients: A Single-Center Retrospective Analysis (ASH 2023) - "All patients received prophylactic antifungal agents, including anti-yeast (fluconazole, n=95), and anti-mold (micafungin n=5, isavuconazole n=1, or Posaconazole n=52). The rate of IFI in our cohort was low (0. 7%) post-CAR T therapy. The diagnostic performance of serial monitoring of B-DG and GM for the diagnosis of IFI is poor in recipients of BCMA-directed CAR T therapy for MM or CD19-directed CAR T for NHL."

CAR T-Cell Therapy • IO biomarker • Retrospective data • Dermatology • Hematological Malignancies • Infectious Disease • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology

Severe Saprochaete capitata fungemia presenting as micafungin breakthrough hepatosplenic lesions in an immunocompromised patient: case report. (PubMed, ASM Case Rep) - "Saprochaete capitata (S. While there is a lack of evidence to guide optimal treatment, the organism appears to exhibit resistance to echinocandins. Expert opinion favors voriconazole as empiric treatment with the addition of intravenous liposomal amphotericin B for severe infections."

Journal • CNS Disorders • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Myelodysplastic Syndrome • Oncology • Schizophrenia

Mycetohabitans rhizoxinica bacteremia in the setting of invasive fungal disease in an immunocompromised patient. (PubMed, ASM Case Rep) - "His surgical treatments included sinus debridement and a near total right pneumonectomy, and his antimicrobial treatment included 10 days of cefepime for his bacteremia, 4 weeks of liposomal amphotericin B, 4 weeks of micafungin following his pneumonectomy, and approximately 12 months of posaconazole. This case highlights the association of M. rhizoxinica with Rhizopus spp., wherein the isolation of M. rhizoxinica led to a high index of suspicion of Rhizopus infection in an immunocompromised patient who developed bacteremia with a slow-growing, oxidase positive, gram-negative bacteria not able to be identified by traditional identification methods."

Journal • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Neutropenia • Oncology • Otorhinolaryngology • Pneumonia • Respiratory Diseases • Sinusitis

From AUC/MIC to AUCss and Cmin: Optimizing Micafungin Therapy in the Critically Ill through Model-Informed Precision Dosing. (PubMed, AAPS J) - "In this heterogeneous ICU cohort, AUCss and Cmin were associated with microbiological outcomes and may offer pragmatic, MIC-independent monitoring metrics. These exploratory findings warrant prospective validation but incorporating simplified, exposure-guided dosing strategies may improve micafungin optimization and clinical outcomes in critically ill populations."

Journal • Critical care • Infectious Disease

Acute Coagulopathy As an Underappreciated Toxicity of Azacitidine/Venetoclax Induction in AML (ASH 2024) - "No other shared mutations were identified.At the time of HMA/Ven initiation two pts were receiving antifungal prophylaxis with the CYP3A4 inhibitor posaconazole and received full-dose Ven (100 mg) on day 1 without ramp up; the other two were receiving micafungin with ramp up Ven dosing. All three pts with de novo AML received hydroxyurea and had WBC <25 x 109/L at the time of HMA/Ven initiation...Our findings suggest that further investigation may be beneficial to determine the real-world incidence of this rare complication and the potential need for additional monitoring guidelines/preventative measures during HMA/Ven induction. Ramp up dosing and close monitoring of TLS/DIC markers should be considered in AML pts receiving HMA/Ven induction."

IO biomarker • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Lung Cancer • Metabolic Disorders • Myelodysplastic Syndrome • Nephrology • Oncology • Renal Disease • Small Cell Lung Cancer • Solid Tumor • IDH1 • IDH2 • TET2

Concurrent Versus Sequential or No Triazole Anti-Fungal Therapy in Patients Undergoing 7+3 Plus Midostaurin Induction for FLT-3 Acute Myelogenous Leukemia (ASH 2023) - " From January 1, 2017, to January 30, 2023, we retrospectively reviewed all adult patients (18 or older) with newly diagnosed AML who received midostaurin in combination with cytarabine and an anthracycline (7+3)...There were no significant differences in baseline characteristics (Table 1) except for more patients receiving isavuconazole (moderate CYP 3A4 inhibitor) in the concurrent group (50% vs 0%; p<0. 01) and more micafungin in the sequential or no azole group (0% vs 72%; p<0... In conclusion, the addition of azole antifungal was found to be equally safe and effective in the treatment of newly diagnosed FTL3 AML. Dose modifications in midostaurin appeared not to be necessary with concurrent azole antifungal therapy. Further analysis based on a larger cohort is needed to confirm the outcomes and safety endpoints reported in the current study."

Clinical • Acute Myelogenous Leukemia • Hematological Malignancies • FLT3

Idarubicin and Cytarabine with and without Midostaurin for FLT3-Mutated Acute Myeloid Leukemia (ASH 2023) - "Background: One of the standards of intensive induction therapy for young patients with acute myeloid leukemia (AML) consists of 7 days of cytarabine and 3 days of either idarubicin 12mg/m 2 (IDA) or daunorubicin 60-90mg/m 2 (DNR) (7+3)...Majority of the patients received micafungin (75%) in the MIDO group and either voriconazole or posaconazole (77%) in the control group... This is the first study to compare the impact of adding MIDO to IDA-based induction versus IDA-based induction alone. Our findings suggest that IDA-based induction may result in a higher cCR rate, with or without the addition of MIDO, when compared to DNR 60mg/m 2 (as per RATIFY). The addition of MIDO to IDA-based induction did not result in increased toxicity."

Acute Myelogenous Leukemia • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Neutropenia • Oncology • FLT3 • NPM1

Evaluation of the Effectiveness of Antifungal Prophylaxis in Adult Acute Lymphoblastic Leukemia during Induction Chemotherapy (ASH 2023) - " Among the 280 patients, 232 received PAP, with caspofungin (n=104), voriconazole (n=59), micafungin (n=44), and others being used as prophylaxis. Our study demonstrates, in a real-life setting, that IFD is a poor prognostic factor for adult ALL and that PAP significantly reduces the incidence of IFD during induction chemotherapy, thereby improving patient survival. Furthermore, compared to published studies (4.3%-18.3%), the incidence of IFD in the prophylaxis group within our cohort is relatively lower. This research was supported by the National Natural Science Foundation of China(NFSC82170163, 81970147), Clinical Study of Nanfang Hospital(LC2016ZD009/2019CR012)."

Clinical • Acute Lymphocytic Leukemia • Dermatology • Hematological Malignancies • Infectious Disease • Leukemia • Oncology • Pediatrics • T Acute Lymphoblastic Leukemia

From Widespread to Tailored Antifungal Prophylaxis in Lymphoma Patients Treated with CD19 CAR T- Cell Therapy: Less Is Better (ASH 2023) - "Group A (2016-2020): patients primarily received fluconazole, as clinically indicated, regardless of clinical risk profile; Group B (2020-2023) standard guidelines were established in 2020 with antifungal prophylaxis recommended only in high-risk patients with prolonged neutropenia (≥ 3 weeks), those on systemic steroids (≥0.5 mg/kg/day of prednisone equivalent) for ≥ 3 days, or in patients with previous IFI; patients were treated based on a more restrictive mold-active and patient-tailored prophylactic strategy...Bridging therapy was administered in 70% of patients in group A and 80% in group B. IFI infections after CAR T-cell therapy were rare: one patient had cryptococcal meningoencephalitis in group A (0.7%) and one had invasive aspergillosis in group B (0.5%), both on micafungin prophylaxis, not effective on molds and cryptococcus... This large single-center cohort of R/R lymphoma patients after CAR T-cell therapy offers a valuable snapshot of two different..."

CAR T-Cell Therapy • Clinical • B Cell Lymphoma • CNS Disorders • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Respiratory Diseases

Evaluating the Effectiveness and Security of Antifungal Prophylaxis in Acute Lymphoblastic Leukemia Induction Chemotherapy (ASH 2024) - "The primary medications administered in PAP included caspofungin (n = 113), voriconazole (n = 99), and micafungin (n = 53). Conclusions : The practical research we conducted revealed that PAP independently safeguards against IFD in ALL patients undergoing induction therapy. Furthermore, caspofungin's safety record for treating PAP in ALL patients is positive."

Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Dermatology • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Myelodysplastic Syndrome • Neutropenia • Oncology

A Case Of STAT3 Hyper-IgE Syndrome Complicated By Scedosporium Pneumonia And ABPA (ACAAI 2025) - "Case Description The patient had multiple bacterial and fungal pneumonias and was started on immunoglobulin replacement and prophylaxis with posaconazole and trimethoprim/sulfamethoxazole...She was subsequently diagnosed with Scedosporium apiospermum pneumonia and was started on voriconazole and terbinafine. On this therapy, she experienced worsening productive cough with continued positive sputum cultures for Scedosporium apiospermum , requiring hospitalization for intravenous micafungin...Her other atopic conditions also improved. Discussion This case highlights the first reported successful use of Dupilumab for ABPA in a patient with HIES."

Clinical • Allergic Bronchopulmonary Aspergillosis • Asthma • Atopic Dermatitis • Cough • Dermatology • Eosinophilia • Eosinophilic Esophagitis • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Musculoskeletal Diseases • Orthopedics • Pneumonia • Primary Immunodeficiency • Respiratory Diseases • STAT3